Certara (CERT) Stock Price, News & Analysis

Company Overview

Certara is a leading provider of model-informed drug development (MIDD) solutions aimed at optimizing the research, development and regulatory approval of therapeutics. The company’s offerings combine advanced computational modeling and simulation technologies with scientific expertise to streamline decision-making across the drug development lifecycle. Its platforms enable pharmaceutical and biotechnology firms to predict drug behavior, design efficient clinical trials and prepare robust regulatory submissions.

The company’s core products include pharmacokinetic and pharmacodynamic modeling tools, physiologically based pharmacokinetic (PBPK) simulation software and trial‐design optimization applications. These software suites are complemented by a range of advisory services in areas such as regulatory strategy, biomarker analysis and real‐world evidence. By integrating quantitative modeling with domain-specific knowledge, Certara helps clients reduce development timelines, manage risk and improve the probability of clinical success.

Founded in 1985 and headquartered in Princeton, New Jersey, Certara has grown through a series of strategic acquisitions and organic investments. The company’s global footprint spans North America, Europe and the Asia‐Pacific region, with offices and research centers established to support local regulatory requirements and scientific collaboration. Over the years, Certara has merged complementary firms to enhance its technological capabilities, including additions in biomarker sciences, bioinformatics and clinical trial simulation.

Certara is led by President and Chief Executive Officer Joseph H. Cleland, who oversees a management team with deep experience in pharmaceutical sciences, engineering and regulatory affairs. Under this leadership, the company continues to expand its modeling and simulation platform, invest in artificial intelligence‐driven analytics and forge partnerships with industry stakeholders to advance the adoption of MIDD across the biopharmaceutical sector.

Key Stats

• Today's Range: $11.19 to $11.50
• 50-Day Range: $10.46 to $13.89
• 52-Week Range: $8.64 to $16.93
• Volume: 1.28 million shs
• Average Volume: 1.45 million shs
• Market Capitalization: $1.84 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.71
• Consensus Rating: Moderate Buy

Certara Stock Analysis - MarketRank™

Certara scored higher than 95% of companies evaluated by MarketBeat, and ranked 60th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Certara has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Certara has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 28.57%

Earnings Growth

Earnings for Certara are expected to grow by 28.57% in the coming year, from $0.28 to $0.36 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Certara is -566.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Certara is -566.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Certara has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.49% of the float of Certara has been sold short.

Short Interest Ratio / Days to Cover

Certara has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Certara has recently increased by 7.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Certara does not currently pay a dividend.

Dividend Growth

Certara does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -0.73

Percentage of Shares Shorted

7.49% of the float of Certara has been sold short.

Short Interest Ratio / Days to Cover

Certara has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Certara has recently increased by 7.69%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.96

News Sentiment

Certara has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Certara this week, compared to 5 articles on an average week.

Search Interest

Only 4 people have searched for CERT on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

MarketBeat Follows

2 people have added Certara to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Certara insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.33% of the stock of Certara is held by insiders.

Percentage Held by Institutions

73.96% of the stock of Certara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CERT Stock Analysis - Frequently Asked Questions

How have CERT shares performed this year?

Certara's stock was trading at $10.65 at the beginning of 2025. Since then, CERT stock has increased by 6.4% and is now trading at $11.33.

How were Certara's earnings last quarter?

Certara, Inc. (NASDAQ:CERT) announced its earnings results on Monday, May, 5th. The company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The company's revenue was up 9.7% on a year-over-year basis.
Read the conference call transcript.

When did Certara IPO?

Certara (CERT) raised $500 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 24,400,000 shares at a price of $19.00-$22.00 per share. Jefferies, Morgan Stanley, BofA Securities, Credit Suisse, Barclays and William Blair acted as the underwriters for the IPO.

How do I buy shares of Certara?

Shares of CERT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Certara own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Certara investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), Opendoor Technologies (OPEN), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Computer Software
• Current Symbol: NASDAQ:CERT
• CIK: 1827090
• Web: www.certara.com
• Phone: 609-716-7900
• Fax: N/A
• Employees: 1,546
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.71
• High Stock Price Target: $18.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +38.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 40.46
• P/E Growth: N/A
• Net Income: -$12.05 million
• Net Margins: -0.67%
• Pretax Margin: -1.83%
• Return on Equity: 5.05%
• Return on Assets: 3.44%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 2.78
• Quick Ratio: 2.78

Sales & Book Value

• Annual Sales: $385.15 million
• Price / Sales: 4.77
• Cash Flow: $0.72 per share
• Price / Cash Flow: 15.75
• Book Value: $6.58 per share
• Price / Book: 1.72

Miscellaneous

• Outstanding Shares: 162,230,000
• Free Float: 158,454,000
• Market Cap: $1.84 billion
• Optionable: Optionable
• Beta: 1.43